Certara (NASDAQ:CERT) Shares Up 11.5% – What’s Next?

Posted by Brian Himes on May 23rd, 2026

Certara, Inc. (NASDAQ:CERT – Get Free Report)’s share price shot up 11.5% on Thursday . The company traded as high as $5.17 and last traded at $5.2050. 2,766,645 shares traded hands during trading, a decline of 18% from the average session volume of 3,370,438 shares. The stock had previously closed at $4.67.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on CERT. Craig Hallum cut their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research report on Tuesday, May 12th. BMO Capital Markets cut their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Tuesday, May 12th. Wall Street Zen lowered shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. Stephens cut their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Finally, Barclays cut their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Certara currently has an average rating of “Hold” and an average price target of $8.85.

Read Our Latest Analysis on Certara

Certara Price Performance

The company’s 50 day simple moving average is $5.80 and its two-hundred day simple moving average is $7.58. The stock has a market capitalization of $815.19 million, a P/E ratio of -52.40 and a beta of 1.53. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88.

Certara (NASDAQ:CERT – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The company had revenue of $106.92 million for the quarter, compared to analyst estimates of $106.13 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. Certara’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities analysts expect that Certara, Inc. will post 0.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

Large investors have recently bought and sold shares of the business. Wasatch Advisors LP raised its holdings in Certara by 45.7% in the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock worth $158,335,000 after purchasing an additional 4,244,230 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of Certara during the fourth quarter worth $26,706,000. Deerfield Management Company L.P. increased its position in shares of Certara by 71.7% during the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after acquiring an additional 2,813,438 shares in the last quarter. Bank of America Corp DE increased its position in shares of Certara by 292.2% during the first quarter. Bank of America Corp DE now owns 2,042,946 shares of the company’s stock worth $11,645,000 after acquiring an additional 1,522,034 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH increased its position in shares of Certara by 133.4% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock worth $20,024,000 after acquiring an additional 1,299,109 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors and hedge funds.

About Certara

(Get Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.